miRNA对骨质疏松症的调控

摘要/Abstract

摘要： microRNA (miRNA)是一种内源性的单链非编码小RNA。通过与靶mRNA的3'UTR结合,参与调控约30%的基因表达,是重要的转录后水平调控因子。在细胞的增殖、分化、凋亡、代谢等生理过程中发挥广泛的作用。研究表明,miRNA与肿瘤、心脏病、糖尿病、帕金森综合症等多种复杂疾病的发生有关,且与多药耐药有关,本文将就miRNA对骨质疏松症的调控等作一综述。

关键词: miRNA, 骨质疏松症, 基因

Abstract: miRNAs are endogenous non-coding single-stranded small RNA molecule and are predicted to regulate 30% of all human genes by targeting mRNA sequences in their 3'UTR. As important post-transcriptional regulators, miRNAs play a positive role in various biological processes, including proliferation, differentiation, apoptosis, metabolism, and so on. Recent studies have indicated that miRNAs are associated with caner, cardiac disease, diabetes, Parkinson syndrome and multidrug resistance. Herein the article reviews the regulation on miRNAs to osteoporosis.

Key words: miRNAs, Osteoporosis, Gene

中图分类号:

R968

王萍, 尹桃, 周伯庭. miRNA对骨质疏松症的调控[J]. 中国临床药理学与治疗学, 2013, 18(1): 110-114.

WANG Ping, YIN Tao, ZHOU Bo-ting. Regulation on miRNA to osteoporosis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 110-114.

参考文献

[1] 刘忠厚. 骨矿与临床[M]. 北京: 中国科学出版社, 2006.
[2] Pandey R, Quinn JM, Sabokbar A, et al.Bisphosphonate inhibition of bone resorption induced by particulate biomaterial-associated macrophages[J]. Acta Orthop Scand, 1996, 67(3): 221-228.
[3] Ferrari SL.Osteoporosis: a complex disorder of aging with multiple genetic and environmental determinants[J]. World Rev Nutr Diet, 2005, 95: 35-51.
[4] Deng HW, Chen WM.Re: “Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions”[J]. Am J Epidemiol, 2000, 151(3): 335-337.
[5] Deng HW, Li JL, Li J, et al.Heterogeneity of bone mineral density across skeletal sites and its clinical implications[J]. J Clin Densitom, 1998, 1(4): 339-353.
[6] Duncan EL, Brown MA.Clinical review 2: Genetic determinants of bone density and fracture risk——state of the art and future directions[J]. J Clin Endocrinol Metab, 2010, 95(6): 2576-2587.
[7] Sigurdsson G, Halldorsson BV, Styrkarsdottir U, et al.Impact of genetics on low bone mass in adults[J]. J Bone Miner Res, 2008, 23(10): 1584-1590.
[8] Duncan EL, Cardon LR, Sinsheimer JS, et al.Site and gender specificity of inheritance of bone mineral density[J]. J Bone Miner Res, 2003, 18(8): 1531-1538.
[9] Bae Y, Yang T, Zeng HC, et al.MiRNA-34c regulates Notch signaling during bone development[J]. Hum Mol Genet, 2012, 21(13): 2991-3000.
[10] Bartel DP.MicroRNAs: target recognition and regulatory functions[J]. Cell, 2009, 136(2): 215-233.
[11] Bartel DP.MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297.
[12] Hassan O, Ahmad A, Sethi S, et al.Recent updates on the role of microRNAs in prostate cancer[J]. J Hematol Oncol, 2012, 5: 9.
[13] Calin GA, Dumitru CD, Shimizu M, et al.Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia[J]. Proc Natl Acad Sci USA, 2002, 99(24): 15524-15529.
[14] Chen KC, Hsi E, Hu CY, et al.MicroRNA-328 may influence myopia development by mediating the PAX6 gene[J]. Invest Ophthalmol Vis Sci, 2012, 53(6): 2732-2739.
[15] Mishra PJ, Humeniuk R, Mishra PJ, et al.A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance[J]. Proc Natl Acad Sci USA, 2007, 104(33): 13513-13518.
[16] Grechukhina O, Petracco R, Popkhadze S, et al.A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis[J]. EMBO Mol Med, 2012, 4(3): 206-217.
[17] 邓红文,Robert R Recker .骨质疏松症的遗传学研究及其基因定位的方法和现状[J]. 中国骨肿瘤骨病, 2002(6): 364-368.
[18] 邓红文,高桂民. 利用病例-父母设计的候选疾病易感基因的LOD值排除分析[J]. 自然科学进展, 2006, 16(5): 563-570.
[19] Swapna N, Vamsi UM, Usha G, et al.Risk conferred by FokI polymorphism of vitamin D receptor (VDR) gene for essential hypertension[J]. Indian J Hum Genet, 2011, 17(3): 201-206.
[20] Hossein-Nezhad A, Varzaneh FN, Mirzaei K.Association of the FokI polymorphism in the vitamin D receptor gene with vertebral fracture in Iranian postmenopausal women[J]. Endocr Pract, 2011, 17(5): 826-827.
[21] Aslani S, Hossein-Nezhad A, Mirzaei K, et al.VDR FokI polymorphism and its potential role in the pathogenesis of gestational diabetes mellitus and its complications[J]. Gynecol Endocrinol, 2011, 27(12): 1055-1060.
[22] Falchetti A, Sferrazza C, Cepollaro C, et al.FokI polymorphism of the vitamin D receptor gene correlates with parameters of bone mass and turnover in a female population of the Italian island of Lampedusa[J]. Calcif Tissue Int, 2007, 80(1): 15-20.
[23] Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al.Multiple genetic loci for bone mineral density and fractures[J]. N Engl J Med, 2008, 358(22): 2355-2365.
[24] Yadav VK, Ducy P.Lrp5 and bone formation : A serotonin-dependent pathway[J]. Ann NY Acad Sci, 2010, 1192: 103-109.
[25] Richards JB, Rivadeneira F, Inouye M, et al.Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study[J]. Lancet, 2008, 371(9623): 1505-1512.
[26] Liao EY, Wu XP, Luo XH, et al.Establishment and evaluation of bone mineral density reference databases appropriate for diagnosis and evaluation of osteoporosis in Chinese women[J]. J Bone Miner Metab, 2003, 21(3): 184-192.
[27] Mclernon DJ, Powell JJ, Jugdaohsingh R, et al.Do lifestyle choices explain the effect of alcohol on bone mineral density in women around menopause[J]? Am J Clin Nutr, 2012, 95(5): 1261-1269.
[28] Silvestri S, Thomsen AB, Gozzini A, et al.Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy[J]? Menopause, 2006, 13(3): 451-461.
[29] Giguere Y, Dodin S, Blanchet C, et al.The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype[J]. J Bone Miner Res, 2000, 15(6): 1076-1084.
[30] Jeon EJ, Lee KY, Choi NS, et al.Bone morphogenetic protein-2 stimulates Runx2 acetylation[J]. J Biol Chem, 2006, 281(24): 16502-16511.
[31] Li H, Xie H, Liu W, et al.A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans[J]. J Clin Invest, 2009, 119(12): 3666-3677.
[32] Zuo J, Jiang J, Dolce C, et al.Effects of basic fibroblast growth factor on osteoclasts and osteoclast-like cells[J]. Biochem Biophys Res Commun, 2004, 318(1): 162-167.
[33] Lei SF, Papasian CJ, Deng HW.Polymorphisms in predicted miRNA binding sites and osteoporosis[J]. J Bone Miner Res, 2011, 26(1): 72-78.
[34] Luzi E, Marini F, Tognarini I, et al.The regulatory network menin-microRNA 26a as a possible target for RNA-based therapy of bone diseases[J]. Nucleic Acid Ther, 2012, 22(2): 103-108.
[35] Luzi E, Marini F, Sala SC, et al.Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor[J]. J Bone Miner Res, 2008, 23(2): 287-295.
[36] Mizuno Y, Yagi K, Tokuzawa Y, et al.miR-125b inhibits osteoblastic differentiation by down-regulation of cell proliferation[J]. Biochem Biophys Res Commun, 2008, 368(2): 267-272.
[37] Goettsch C, Rauner M, Pacyna N, et al.miR-125b regulates calcification of vascular smooth muscle cells[J]. Am J Pathol, 2011, 179(4): 1594-1600.
[38] Li Z, Hassan MQ, Volinia S, et al.A microRNA signature for a BMP2-induced osteoblast lineage commitment program[J]. Proc Natl Acad Sci U S A, 2008, 105(37): 13906-13911.
[39] Wang Y, Li L, Moore BT, et al.MiR-133a in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis[J]. PLoS One, 2012, 7(4): e34641.
[40] 廖二元. 更新知识、规范诊疗——应对骨质疏松症的高患病率[J]. 药品评价, 2012, 9(7): 6-8.
[41] John A, Goldman M.The Women's Health Initiative 2004-Review and Critique: Osteoporosis and Fractures[J]. Med Gen Med, 2004, 6(3): 65.
[42] Vanella L, Sanford CJ, Kim DH, et al.Oxidative stress and heme oxygenase-1 regulated human mesenchymal stem cells differentiation[J]. Int J Hypertens, 2012,2012: 890671.
[43] Mori S.Aim of the guidelines for the prevention and treatment of osteoporosis (2011 edition). Concomitant treatment of the osteoporotic drugs[J]. Clin Calcium, 2012, 22(6): 904-910.